3 results  1 of 1 

1 Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients
Hyery Kim, Hyoung Jin Kang, Kyung Duk Park, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Hack Ki Kim, Jae Min Lee, Jeong Ok Hah, Jun Ah Lee, Young Ho Lee, Sang Kyu Park, Hee Jo Baek, Hoon Kook, Ji Yoon Kim, Heung Sik Kim, Hwang Min Kim, Hee Won Chueh, Meerim Park, Hoi Soo Yoon, Mee Jeong Lee, Hyoung Soo Choi, Hyo Seop Ahn, Yoshifumi Kawano, Ji Won Park, Seokyung Hahn, Hee Young Shin
Cancer Res Treat.2019;51(1):357-367.   Published online 2018 May 14     DOI: http://dx.doi.org/10.4143/crt.2017.457
      
2 Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
In-Ho Kim, Ji Eun Lee, Ho-Joong Youn, Byung Joo Song, Byung Joo Chae
J Breast Cancer.2017;20(1):82-90.   Published online 2017 March 24     DOI: http://dx.doi.org/10.4048/jbc.2017.20.1.82
      
3 Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
Hyoung Soo Choi, Eun Sil Park, Hyoung Jin Kang, Hee Young Shin, Chung Il Noh, Yong Soo Yun, Hyo Seop Ahn, Jung Yun Choi
J Korean Med Sci.2010;25(9):1336-1342.   Published online 2010 August 12     DOI: http://dx.doi.org/10.3346/jkms.2010.25.9.1336
      

 1 of 1